FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US January 14, 2025
Neogap Therapeutics partners with NorthX Biologics to advance scalable manufacturing for its novel cancer cell therapy November 4, 2024
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab) October 30, 2024
